Clinical Trial Update: Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase II study of the CD38 antibody daratumumab in high-risk monoclonal gammopathy of undetermined significance (MGUS) and low-risk smoldering multiple myeloma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Undetermined Significance
• Smoldering Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Monoclonal Gammopathy, Smoldering Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-27